Inactive Instrument

Inter Pharma Stock OTC Markets

IPTB.F

TH9474010005

Interpharma Public Company Limited is a Thailand-based company that develops, researches and distributes healthcare products and beauty initiatives for human beings, and healthcare products for animals. The Company provides wellness and anti-aging products, aesthetic innovation products, companion animal health products and livestock products. Its products include PREBO, YUUU toothpaste, multivitamin, Probac 7, Probac 10, Beta Glucan Plus, Pure Krill Oil, Astacurmin, YUUU cleansing mousse, Perfectha Complement, Perfectha Derm, Perfectha Deep, Perfectha Subskin and Uderma.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	3.21B 94.89M 83.46M 77.48M 71.25M 134M 9.16B 136M 926M 361M 4.49B 356M 349M 15.73B	P/E 2024	52.3x	P/E 2025	22.8x
Enterprise Value	3.33B 98.42M 86.56M 80.37M 73.9M 139M 9.5B 141M 960M 375M 4.66B 369M 361M 16.32B	EV / Sales 2024	1.13x	EV / Sales 2025	1.31x
Free-Float	-	Yield 2024 *	-	Yield 2025	1.59%

05-11	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-02	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-01	Inter Pharma Public Company Limited announces Annual dividend, payable on May 25, 2026	CI
11-11	Inter Pharma Public Company Limited (SET:IP) agreed to acquire an additional 49% stake in Interpharma- ZEAvita Company Limited from Thai Union Ingredients.	CI
11-11	Inter Pharma Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-14	Inter Pharma Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-13	Inter Pharma Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-16	Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal	MT
25-04-16	Zhaoke Ophthalmology Limited Enters into Three Distribution and Supply Agreements with Interpharma Public Company Limited	CI
25-04-01	Inter Pharma Public Company Limited Signs Exclusive Distribution Agreement with Zhaoke Ophthalmology Company Limited for Comprehensive Eye Care Innovation	CI
25-02-25	Inter Pharma Public Company Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-25	Inter Pharma Public Company Limited Proposes to Omit Dividend Payment for the Year Ended December 31, 2024	CI
24-11-13	Inter Pharma Public Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

22-08-16	Inter Pharma : New shares of IP to be traded on August 18, 2022	PU
22-08-10	Inter Pharma Public : Notification on Change of Directors and Authorization of Directors	PU
22-08-10	Inter Pharma Public : Report on the results of sale of common shares offered to private placement (F53-5)	PU
22-08-10	Inter Pharma Public : Right Adjustment of IP-W1 (Edited)	PU
22-08-09	Inter Pharma Public : Right Adjustment of IP-W1	PU

Manager	Title	Age	Since
Trinnawat Thanitnithiphan CEO	Chief Executive Officer	56	2014-01-31
Chatkaew Krudkosol DFI	Director of Finance/CFO	56	2023-06-22
Chompunuch Meevang CMP	Compliance Officer	54	-

Director	Title	Age	Since
Napaporn Dechakarat BRD	Director/Board Member	51	2017-06-13
Sansanee Chaiyaroj BRD	Director/Board Member	64	2020-07-31
Trinnawat Thanitnithiphan BRD	Director/Board Member	56	2014-01-31

Inter Pharma Stock OTC Markets

Stocks

IPTB.F

TH9474010005

Pharmaceuticals

Valuation: Inter Pharma

Latest news : Inter Pharma

Press Releases: Inter Pharma

Managers and Directors: Inter Pharma

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTER PHARMA	-.--%	-.--%	-	-	92.33M
ELI LILLY AND COMPANY	+1.97%	+2.53%	+52.73%	+156.66%	1,037B
JOHNSON & JOHNSON	+1.42%	+4.96%	+54.39%	+52.34%	615B
ABBVIE INC.	+1.43%	+5.25%	+37.31%	+78.74%	448B
ROCHE HOLDING AG	+5.14%	+5.84%	+37.54%	+27.28%	326B
NOVARTIS AG	+1.85%	+4.64%	+38.53%	+39.87%	293B
ASTRAZENECA PLC	-0.11%	+0.97%	+22.57%	+17.81%	264B
NOVO NORDISK A/S	+0.25%	-3.10%	-24.44%	-42.25%	216B
AMGEN INC.	+1.49%	+3.68%	+21.53%	+58.21%	198B
GILEAD SCIENCES, INC.	+0.40%	-0.64%	+18.78%	+62.28%	162B
Average	+0.75%	+1.12%	+28.77%	+50.10%	395.27B
Weighted average by Cap.	+0.51%	+1.47%	+38.33%	+75.23%

	2024	2025
Net sales	1.91B 56.55M 49.74M 46.18M 42.46M 79.59M 5.46B 81.14M 552M 215M 2.68B 212M 208M 9.38B	2.21B 65.49M 57.59M 53.47M 49.17M 92.17M 6.32B 93.97M 639M 249M 3.1B 246M 241M 10.86B
Net income	37.28M 1.1M 970K 900K 828K 1.55M 106M 1.58M 10.76M 4.2M 52.18M 4.14M 4.05M 183M	122M 3.62M 3.18M 2.96M 2.72M 5.09M 350M 5.19M 35.32M 13.78M 171M 13.58M 13.29M 600M
Net Debt	209M 6.18M 5.43M 5.05M 4.64M 8.7M 597M 8.87M 60.3M 23.52M 292M 23.19M 22.69M 1.02B	119M 3.53M 3.1M 2.88M 2.65M 4.97M 341M 5.06M 34.43M 13.43M 167M 13.24M 12.96M 585M